Drug Formulation Congress 2019

Theme: Frontier Novelties in Drug Formulations & Drug Delivery

Drug Formulation Congress 2019

17^th International Conference on Drug Formulation & Drug Delivery is scheduled to be held during September 25-26, 2019 at Hong Kong. This Pharmaceutical Conferences 2019 includes a wide range of Keynote presentations, plenary talks, Symposia, Workshops, Exhibitions, Poster presentations and Career development in Pharma

Series Ltd Organizes Conference 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The Conference Series LLC ltd website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Drug Formulation Congress 2019 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about drug formulation and drug delivery and its advances. This is your best opportunity to reach the largest assemblage of participants from Pharma research community that is from academia in the Pharmaceutical Conferences 2019, drug delivery entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.

Drug Formulation Congress 2019 will discuss various disciplines involved in the drug formulation procedures and Novel Drug Delivery Conferences; it will educate health care researchers about drug formulation and drug design, operation, organizing, research computing Regulatory aspects` and reporting of formulations. This conference conduct presentations, distribute information, meet with current and potential scientists, make a splash with new Pharma Research developers in Pharma research Conferences and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in formulations and drug delivery are hallmarks of this Pharma Event, Pharmaceutical Conferences 2019

Who should attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of

CROs and CMOs
Pharma Research Sites
Pharma/Biotech and Medical Device industries
Hospitals, Associations

Pharmaceutical Conferences 2019, Drug Formulation Congress 2019,Novel Drug Delivery Congress, Medical Directors, Principal Investigators, Methodologists, and other Drug Formulation Experts, Drug Formulation Professors, Drug Formulation Graduates, Pharma Research professionals in Pharma Research Conferences along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professors, Research Scholars, scientists who are related to drug formulation pharmaceutical research.

Target Audience

PhD Scholars in Drug Formulation
PhD in Pharmaceutical Sciences
Graduates and Post Graduates in Pharmaceutics
Pharmaceutical Science Professors, Associate Professors, Assistant Professors
Bio instruments Professionals
Bio-informatics Professionals
Directors, CEO’s of Organizations
Supply Chain companies
Pharmaceutical Manufacturing Companies
Software development companies
Drug Formulation Research Institutes and members

Track 1: Drug Design & Development

Pharmaceutical Conferences 2019 describes drug design is the method of inventing innovative medications. Drug design and Drug formulation defines the design of molecules that are corresponding in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which repeatedly results in a medicinal benefit to the patient. Discovery of drugs and Drug formulation is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether conversations occur. Basically, Drug Formulation and drug design involves drug design of small molecules that are harmonizing in shape and charge to the bio molecular target to which they act together and consequently will bind to it.

7^th European Biosimilars Conference, April 26-27, 2018, Rome, Italy; 10^th Pharmacology Conferences, Jul 30-Aug 01, 2018 at Barcelona, Spain; Formulations Conferences 2018 USA, 4^th Natural Products Conferences, June 11-13, 2018 at Rome, Italy; 8^th Environmental Chemistry Conference, September 20-22, 2018 Berlin, Germany; 9^th Pharmacovigilance Exhibition, June 21-22, 2018 at London, UK; 4^th Antibiotics Conference; June 14-15, 2018, Barcelona, Spain; Formulation Conferences 2018 Europe, 13^th European Pharma Conferences May 07-09, 2018 at Frankfurt, Germany.

Biopharmaceutics Technology Meeting, March 19-22, 2018, Granada, Spain; 15^th Annual European Pharma Congress May 07-09, 2018 Frankfurt, Germany; Conference on Supply Chain Security October 24-26, 2018 Berlin, Germany; World Congress of Pharmacy September 02-06, 2018, Glasgow, UK.

Related Pharma Societies:

Related Journals:

Journal of Pharmacology and Therapeutics; Journal of Therapeutic Advances in Drug Safety; Journal of Clinical Pharmacokinetics; Journal of Investigational New Drugs; Journal of Pharmaceutical Research, Journal of Drugs; Drug Metabolism Reviews, A Journal of Drug Formulation, Development and Production; Recent Patents on Drug Delivery & Formulation, Journal of Toxicology: Clinical Toxicology, Journal of Molecular Pharmaceutics & Organic Process Research, The pharmaceutical Journals.

Track 2: Computer Aided Drug Design (CADD)

The processes of designing a new drug by using bioinformatics implements have opened a new area of drug research and development. Computational techniques assist us in searching drug target and in Drug Formulation designing drug. Pharmaceutical Conferences 2019, Bioinformatics affects drug formulation and new drug design in the following drug design path

By using computational methods and the 3D structural information of the protein target, we are now able to scrutinize the detailed underlying molecular and atomic interactions involved in ligand: protein interactions and thus interpret experimental results in detail. The use of computers in drug formulation and drug discovery bears the additional advantage of delivering new drug candidates more rapidly and cost-efficiently. Computer-aided drug discovery has recently had important successes in drug formulation: new ligands have been predicted along with their receptor-bound structures and in several circumstances the achieved hit rates (ligands discovered per molecules tested) have been significantly greater than through experimental high-throughout screening. Strategies for CADD vary depending on the extent of structural and other information available regarding the target (enzyme/receptor) and the ligands.

Related Pharma Societies:

Related Journals:

Track 3: Biomarkers in Drug Design

TechnAssociation of British Pharmaceutical Industry, Indian Society for Clinical Organization Researchological advancements in the molecular characterization of cancers have assisted researchers to identify an increasing number of key molecular drivers of cancer progression. These drug discoveries have led to multiple novel anticancer therapeutics, and clinical advantage in selected patient populations. Despite this, the identification of clinically relevant predictive biomarkers of response continues to lag behind. In this review, we discuss strategies for the molecular characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.

The discovery and evaluation of any novel biomarkers will ideally be specialized to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers and are crucial to accelerating the drug development process.

Related Pharma Societies:

Related Journals:

Track 4: Pre-Formulation & Formulation Aspects

Drug Formulation is the study of relationships between pre-formulation, pharmaceutical formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its preferred form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was restricted only for assessing few characteristics, but today this process is being considered as a formulation strategy and hence tremendous technological advancement has been accomplished in this field which enables us to save time and money through planned management system and hence impacts Drug Formulation 2017 to be a Drug Formulation Conference. Use of glorious statistical software even based on artificial neural networking are made the task of pre-formulation and optimization process easier. Role of pre formulation studies techniques like freeze drying aspects projects the event Drug Formulation 2017 to pose as a freeze drying meeting in drug discovery, drug development plays major role in pharmaceutical drug formulation development and the revisions will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of drug formulations unique to each drug. NDDS conference will discuss on Premature Approaches, Present Scenario and Future Prospects of Pre-formulation events. There are more than 1400 sustained or controlled release drugs have been approved all over the world. Pharmaceutical conferences discuss the state-of-art technology being applied and involve advances in drug formulation studies.

Related Pharma Societies:

Related Journals:

Track 5: Pharmacokinetics & Pharmacodynamics

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics and drug formulation include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.

Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of achievement is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall

Related Pharma Societies:

Related Journals:

Track 6: Clinical Trails & Biotherapeutics

Clinical Biotherapeutic aspects including study drug formulations, drug design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.

Related Pharma Societies:

Related Journals:

Track 7: Innovative Drug Discovery and Nanotechnology

Size reduction is a fundamental unit operation having important applications in Pharmaceutical Sciences, Drug Formulations. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better drug formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nano meter size range enhance performance in a variety of dosage forms. Major advantages of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.

Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative and highly specialized field, which will revolutionize the pharmaceutical industry in near future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against many diseases. It helps in detecting the antigen associated with diseases such as cancer, diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and viruses associated with infections. It is expected that in next 10 years market will be flooded with nanotechnology devised medicine.

Related Pharma Societies:

Related Journals:

Track 8: Novel Drug Delivery System

Identifying drug targets plays essential roles in designing new drugs, drug formulations and combating diseases. Unfortunately, our current understanding about drug targets is far from comprehensive. Screening drug targets in the lab is an expensive and time-consuming procedure. In the past decade, the accumulation of various types of study of science related data makes it possible to develop computational approaches to predict drug targets. Non-communicable diseases such as cancer, atherosclerosis and diabetes are responsible for most important social and health affliction as millions of people are dying every year. Out of which, atherosclerosis is the leading cause of deaths worldwide. The lipid abnormality is one of the most important modifiable risk factors for atherosclerosis. Both genetic and environmental components are associated with the development of atherosclerotic plaques. Immune and inflammatory mediators have a complex role in the initiation and progression of atherosclerosis. Understanding of all these processes will help to invent a range of new biomarkers and novel treatment modalities targeting various cellular events in acute and chronic inflammation that are accountable for atherosclerosis. Several biochemical pathways, receptors and enzymes are involved in the development of atherosclerosis that would be possible targets for improving strategies for disease diagnosis and management.

Related Pharma Societies:

Related Journals:

Track 9: Medicinal Chemistry & Drug Discover Advancements

Medicinal Chemistry is a branch of chemistry which especially agreements with synthetic organic chemistry and pharmacology including various other biological specialties which is involved with design. It combines knowledge and capacities from the fields of cheminformatics, molecu, chemical creation and development of drug formarketing of pharmaceutical agents lar modeling and important bioinformatics and drug formulations, demands an in-depth appreciative of the physico-chemical properties of a three-dimensional molecule. The information base required by today's medicinal chemist has increased dramatically and has highlighted an rising challenge for chemists to understand the growing field of drug design.

Related Pharma Societies:

Related Journals:

Track 10: Drug Product Manufacturing

Drug manufacturing (Pharmaceutical Manufacturing) is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug formulations can be demolished down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others. The changing pharmaceutical landscape is a popular discussion point as of late. Armed with a fresh, non-blockbuster-reliant business model and treatment options that are expanding from small molecules to a range of new, more targeted therapies, the industry is at what PwC calls, “a critical juncture.”

Parenteral drug delivery, Novel Drug Delivery is the second largest segment of this transformative pharmaceutical market covered only by the more mature oral solid dosage forms accounting for nearly 30 percent of total Pharma market share. According to Survey, the market for parenteral drug delivery products is projected to rise over 10 percent annually to $86.5 billion in 2019.

Related Pharma Societies:

Related Journals:

Track 11: Chemical and Pharmaceutical Engineering

Pharmaceutical engineering is a branch of pharmaceutical science and technology that involves development and manufacturing of products, processes, and components in the pharmaceuticals industry (i.e. drugs & biologics). While developing pharmaceutical products involves many interrelated disciplines (e.g. medicinal chemists, analytical chemists, clinicians/pharmacologists, pharmacists, chemical engineers, biomedical engineers, etc.), the specific subfield of "pharmaceutical engineering" has only emerged recently as a divergent engineering discipline. This now brings the problem-solving principles and quantitative training of engineering to complement the other scientific fields already involved in drug formulations

Related Pharma Societies:

Related Journals:

Track 12: Pharmaceutical Regulatory Affairs

Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. The pharmaceutical industry deals with an increasing number of interesting drug candidates, all of which necessitate the involvement of the Regulatory Affairs’ department. Regulatory Affairs professionals can play a key role in guiding drug formulations strategy in an increasingly global environment. But they also play an important operational role, for example, by considering the best processes to follow and enabling structured interaction with regulatory authorities. Regulatory Affairs is driven by good science and accordingly nothing remains static.

Related Pharma Societies:

Related Journals:

Track 13: Bioequivalence Studies and Assessment

Bioequivalence studies are done for both Early & late Clinical Trial formulations, Drug formulations used in clinical trials and stability studies, if different Clinical trial formulations and to-be-marketed drug product when it comes to cost and productivity metrics, it’s often said that what gets measured gets done. Bioequivalence is determined based on the bioavailability of the innovator medicine versus the generic medicine. The outline for bioequivalence study includes the organization of test and reference items on two events to volunteer subjects, with every organization isolated by a washout period. This Study involves parameters on (Cmax) and (AUC), Statistical evaluation.

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.

Related Pharma Societies:

Related Journals:

Track 14: Recent advancements in BA/BE Research

The aim of bioavailability study is to find out the dosage form influence on the biological performance of the drug, sensitivity to detect differences in the rate and extent of absorption. Bioavailability and bioequivalence study design involves Single dose or multi dose standard 2x 2 crossovers, Parallel groups, for more than two drug formulations. Study drug design meant for estimating essential pharmacokinetic parameters differs significantly from a bioequivalence study meant for comparing the test formulation. The results of a pilot study can be used as the sole basis to document BA or BE provided the study’s design and execution are suitable and enough subjects have completed the study

Related Pharma Societies:

Related Journals:

Track 15: Business Opportunities in Drug Delivery

The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% in 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in increasing number of drug delivery specialists. Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, drug formulation, quality control, and business development Business opportunities in drug delivery.

Related Pharma Societies:

Related Journals:

Track 16: NMR and Analysis of Small Organic Molecules

In bioscience and drugs, to small grade molecule may be a coffee mass (<900 Daltons [1]) compound which is incapable to facilitate regulate a process, with a size on the order of 10−9 m. Most drug analysis square measure identical little molecules. For analysis of small organic molecules the subsequent devices ought to be recycled are as follows HPLC method, Chromatography, Ultraviolet-visible (UV-VIS) spectrophotometry, Infrared (IR) spectrometry and Mass spectrometry.

Related Pharma Societies:

Related Journals:

Drug Formulation Congress 2019 and Novel Drug Delivery Conferences will discuss effective drug formulation and drug delivery technologies for enhancing solubility and drug delivery. Drug Formulation Congress 2019 aims to aggregate leading experts from around the world who will discuss on drug formulation and drug delivery, and show how they are developing poorly soluble drugs into scientifically sound, patient-centric drug formulations, and reducing their product development timelines

Active Pharmaceutical Ingredient Market:

Transparency Market research states the opportunity in this market will be worth US$219.60 bn by 2023 from US$134.7 bn in 2015. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%

The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021. The rising demand for new drug delivery systems, greater understanding of the functional benefits of excipients, growing pharmaceutical industry, and patent expiries of several blockbuster drugs are positively impacting the overall growth of the market.

Major Pharmaceutical Companies in Hong Kong:

Apollo Fine Chemical Inc.
Delta Hi Tech Industry Co. LTD
Champollion International Ltd.
Vikn Trading Ltd
Pacific International Traders
Far-East Trade (HK) Ltd
Grace Union Enterprise Development Limited
Vitar Solutions Limited
Einstain Fine Chemical Inc.
Columbia International
Jiwa Bio-pharm Holdings Limited
Hong Kong Cow Chemical Co., Ltd.
Hong Chuang International Trade Co., Ltd.

Major Associations around the Globe:

Pharmaceutical Research and Manufacturers of America
Regulatory Affairs Professionals Society
International Society of Pharmaceutical Compounding (ISPhC)
International Young Pharmacists' Group (YPG)
Parenteral Drug Association (PDA)
Regulatory Affairs Professionals Society (RAPS)
Controlled Release Society
Society for biomaterials
Washington State Pharmacy Association
Inhalation Drug Delivery Association
International society of drug delivery sciences and technology.
American Association of Pharmaceutical Scientist

Top Pharma Universities in Hong Kong:

The University of Hong Kong
The Chinese University of Hong Kong

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	September 25-26, 2019
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View